Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21816275 | 0.77 | F2 (0.46) | ALDH1A1HPGDKDM4ESMN1; SMN2ELANE | |
| SCHEMBL4338282 | 0.72 | KDM4E (0.50) | ALDH1A1HPGDKDM4ESMN1; SMN2CA1 | |
| SCHEMBL27880869 | 0.70 | KDM4E (0.52) | KCNMA1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL8121292 | 0.69 | LMNA (0.46) | KCNMA1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL166053 | 0.68 | FOLH1 (0.32) | — | |
| SCHEMBL10431336 | 0.67 | HPGD (0.54) | KCNMA1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL6920277 | 0.67 | KCNMA1 (0.51) | KCNMA1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL8009694 | 0.67 | KDM4E (0.44) | KCNMA1ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL11718417 | 0.66 | MEN1 (0.61) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| SCHEMBL31347868 | 0.66 | MEN1 (0.61) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897085-A | A kind of tripterygium wilfordii derivative and application | 上海健康医学院 | 2019-06-18 | — | — | CN | disclosed |
| CN-103890010-B | Anti-human-HER3 antibodies and uses thereof | 法国国家健康医学研究院 | 2017-04-19 | — | — | CN | disclosed |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-02-23 | — | — | US | disclosed |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| CN-103890010-A | Anti-human-HER3 antibodies and uses thereof | INST NAT SANTE RECH MED | 2014-06-25 | — | — | CN | disclosed |
| US-20130197210-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8277846-B2 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120172525-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALANDO PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8092833-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20060182795-A1 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-08-17 | — | — | US | disclosed |
| US-7018609-B2 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1351710-A2 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030017972-A1 | Complexing agents for compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC | 2003-01-23 | — | — | US | disclosed |
| US-20030008818-A1 | Compositions containing inclusion complexes | CALIFORNIA INSTITUTE OF TECHNOLOGY AND INSERT THERAPEUTICS, INC | 2003-01-09 | — | — | US | disclosed |
| WO-2002049676-A2 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-06-27 | — | — | WO | disclosed |
| US-6403713-B2 | CROSSLINKING WITH PHENOL-FORMALDEHYDE RESIN, 3-(N-SALICYLOYL) AMINO-1,2,4-TRIAZOLE, AND HYDRAZIDE FORMING BUTYL RUBBER; RESILIENT AND LOW CORROSIVITY; HALOGEN-FREE | ONIZAWA MASAO (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20010027235-A1 | Method for crosslinking of isoprene-isobutylene rubber, ethylene-propylene-diene rubber containing ethylidenenorbornene as unsaturated component, or mixture thereof; and crosslinked rubber product obtained by said method | ONIZAWA MASAO (JP) | 2001-10-04 | — | — | US | disclosed |
| WO-1996030407-A1 | BIFUNCTIONAL THROMBIN INHIBITORS BEARING HIGHLY TRUNCATED FIBRINOGEN RECOGNITION EXOSITE BINDING COMPONENT | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1996-10-03 | — | — | WO | disclosed |
| CN-85109633-A | Process for the preparation of antibiotic derivatives | — | 1987-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008818-A1 | Compositions containing inclusion complexes | EXOSC5, EXOSC9, INTS6 | KCNMA1 4082/4885ALDH1A1 2718/4885HPGD 2122/4885 |
| US-20150031753-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | KCNMA1 4096/4885ALDH1A1 3199/4885HPGD 1798/4885 |
| US-20060182795-A1 | Compositions containing inclusion complexes | INTS6, EXOSC5, EXOSC9 | KCNMA1 4289/4885ALDH1A1 3373/4885HPGD 1727/4885 |
| US-20030017972-A1 | Complexing agents for compositions containing inclusion complexes | INTS6, EXOSC5, PCBP1 | KCNMA1 3873/4885ALDH1A1 2762/4885HPGD 1866/4885 |
| US-20150050233-A1 | COMPOSITIONS CONTAINING INCLUSION COMPLEXES | EXOSC5, EXOSC9, INTS6 | KCNMA1 4187/4885ALDH1A1 2996/4885HPGD 2109/4885 |
| US-20170049903-A1 | COMPLEXING AGENTS FOR COMPOSITIONS CONTAINING INCLUSION COMPLEXES | INTS6, EXOSC5, PCBP1 | KCNMA1 4096/4885ALDH1A1 3199/4885HPGD 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.